Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Geron Corporation

A Decade of SG&A Trends in Biotech Giants

In the ever-evolving biotech industry, operational efficiency is paramount. Over the past decade, Pharming Group N.V. and Geron Corporation have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Pharming Group N.V. saw a staggering increase of over 3,000% in SG&A expenses, peaking in 2022. This reflects their aggressive expansion and strategic investments. In contrast, Geron Corporation's SG&A expenses grew by approximately 312%, indicating a more conservative approach. Notably, 2023 marked a pivotal year where Geron Corporation's expenses surged by 58% compared to the previous year, hinting at potential strategic shifts. These trends underscore the dynamic nature of the biotech sector, where companies balance growth with operational costs. As the industry continues to innovate, understanding these financial patterns offers valuable insights into corporate strategies and market positioning.